1. Brief introduction to project sponsor

Shandong Kejin Biological Development Co was established in Jinan in 2020. The company is located on the fourth floor of the Science and Technology Finance Building in Changqing district. The company has a registered capital of 15 million yuan ($2.33 million) and currently has 22 employees.

Its main business includes stem cell technology development, technical services, technology transfer, technical consulting, stem cell and immune cell storage technical services, medical research and experimental development, health management consulting, clinical laboratory services, daily necessities, cosmetics, medical equipment, laboratory equipment and consumables, chemical reagents (excluding dangerous goods), as well as wholesale and retail of pre-packaged food and bulk food.

The company's chief scientist professor Wen Xuejun has applied for more than 10 patents and nine core technologies with independent intellectual property rights. Traditional surgical therapy, interventional therapy, local therapy, 3D organ tissue printing technology, as well as new materials of human tissues and organs are jointly applied in clinical research.

In the future, the company will realize the full range of cell regenerative medicine through precision treatment of regenerative medicine, opening up many related fields like health management, hospital medical treatment, rehabilitation and health care, anti-aging beauty, and many other related fields, forming the whole industrial chain.

2. Overview of cooperation

The company's main business:

(1) Build production bases and shared laboratories to complete the development layout of the cell industry chain.

(2) Lay out industrial development and create a new operation mode of the cell industry.

(3) Expand to cell upstream industries, such as storage, biological sample bank construction, culture medium production, and biological materials.

(4) Establish a fund to set up cooperative enterprises with scientists based on "laboratory + investment" model. (Mainly holding shares, but also including equity participation and innovation cooperation.)

Shandong Kejin Biological Development Co cooperated with Shanghai Dongfang Hospital and Shandong First Medical University to establish the Shandong Provincial Stem Cell Technology Innovation Center.

It established the Chinese Academy of Regenerative Medicine Transformation Research Institute with the Chinese Academy of Sciences, Chinese Science Health Industry Section.

It established a joint laboratory for regenerative medicine with Shandong First Medical University, which is located on the Zhangqiu campus of Shandong First Medical University.

It reached a strategic partnership agreement with Binzhou Medical College and signed a contract to jointly build a stem cell and regenerative medicine application transformation center.

3. Prospect analysis

(1) Current status and prospects of the industry

In recent years, many provinces and cities across the country have successively announced the development of the cell industry as a key industry.

In 2019, Jinan also listed the cell industry as one of the top 10 billion-yuan industries to support its development. In particular, the approval of the Jinan area of the pilot free trade zone will usher in greater opportunities for the cell industry.

(2) Market scale

According to the data from the 2018-2024 China Stem Cell Therapy Industry Analysis and Investment Decision Consulting Report released by Zhiyan Consulting, the scale of China’s stem cell therapy market reached 31.55 billion yuan in 2017.

The industry will continue to develop rapidly in the next few years, the market demand is large, and the prospects are broad. It is projected that the market scale of stem cells and regenerative medicine-related fields in China will exceed 35 billion yuan in 2021.

(3) Financial forecast

(4) The company's profit forecast for the next three years is 1 billion yuan in cumulative sales revenue.

4. Cooperation Mode

Project category: New project

Cooperation Mode: Equity investment

Project implementation cycle: The project is to be listed on the Science and Technology Innovation Board in three years, generating 60 billion yuan in revenue.

5. Contact information

Contact: Gu Xiaomei or Jiang Tianqi

Tel: +86-189-6307-6517 or 0531-8815-3206

Email: guxiaomeiz@163.com